Consolidative and salvage thoracic radiotherapy (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) with first-line chemoimmunotherapy: a retrospective study from a single cancer center

被引：0
|
作者：
Lan, Aihua [1 ,2 ,3 ,4 ]
Dong, Huiling [1 ]
Zheng, Zhiqin [5 ]
Chu, Xiao [1 ,2 ,3 ,4 ]
Zhu, Zhengfei [1 ,2 ,3 ,4 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Shanghai Clin Res Ctr Radiat Oncol, Shanghai, Peoples R China
[4] Shanghai Key Lab Radiat Oncol, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Minhang Branch Hosp, Dept Radiat Oncol, Shanghai, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2025年 / 55卷
关键词：
Extensive-stage small-cell lung cancer; Immunotherapy; Survival; Thoracic radiotherapy;
D O I：
10.1016/j.lanwpc.2024.101373
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S509 - S510
  • [22] Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer.
    Slotman, Ben J.
    Faivre-Finn, Corinne
    van Tinteren, Harm
    Praag, John
    Knegjens, Joost
    El Sharouni, Sherif
    Hatton, Matthew
    Keijser, Astrid
    Senan, Suresh
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
    Dragnev, K. H.
    Owonikoko, T. K.
    Csoszi, T.
    Maglakelidze, M.
    Beck, J. T.
    Gomez, M. Domine
    Lowczak, A.
    Fulop, A.
    Hoyer, R. J.
    Hanna, W.
    Lowry, P.
    Aljumaily, R.
    Chiu, V. K.
    Bulat, I.
    Yang, Z.
    Roberts, P. J.
    Antal, J. M.
    Malik, R. K.
    Morris, S. R.
    Weiss, J. M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Consolidative thoracic radiotherapy for extensive stage small cell lung cancer
    Zhang, Xiaoli
    Yu, Jinming
    Zhu, Hui
    Meng, Xue
    Li, Minghuan
    Jiang, Liyang
    Ding, Xingchen
    Sun, Xindong
    ONCOTARGET, 2017, 8 (13) : 22251 - 22261
  • [25] Patterns of Disease Progression after Carboplatin/Etoposide plus Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
    Higgins, K. A.
    Curran, W. J., Jr.
    Liu, S. V.
    Yu, W.
    Brockman, M.
    Johnson, A.
    Bara, I.
    Bradley, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (05): : 1398 - 1398
  • [26] Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
    Sorrentino, J. A.
    Lai, A.
    Weiss, J. M.
    Dragnev, K. H.
    Owonikoko, T. K.
    Adler, S.
    Antal, J. M.
    Malik, R. K.
    Roberts, P. J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis
    Hoffmann, Elgin
    De-Colle, Chiara
    Potkrajcic, Vlatko
    Baumann, David
    Spengler, Werner
    Gani, Cihan
    Utz, David
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 (07) : 668 - 675
  • [28] Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
    Nadler, Eric S.
    Vasudevan, Anupama
    Davies, Kalatu
    Wang, Yunfei
    Johnson, Ann
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Is consolidative thoracic radiotherapy of extensive-stage small cell lung cancer still beneficial in the era of immunotherapy? A retrospective analysis
    Elgin Hoffmann
    Chiara De-Colle
    Vlatko Potkrajcic
    David Baumann
    Werner Spengler
    Cihan Gani
    David Utz
    Strahlentherapie und Onkologie, 2023, 199 : 668 - 675
  • [30] Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345